RxDoctor Payments Data

Carl Kinzel, DO

Family Medicine · Battle Creek, MINPI 1992983209

Payments from drug & device makers

$11,976in general payments, 2019–2025

Across 723 payments — averaging $16.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Amgen$1K
  • Lilly USA, LLC$852
  • AstraZeneca$842
  • Pfizer$771
  • AbbVie$764
  • plus $5K from 42 others

What the payments were for

  • Food & beverage$11,82699%
  • Education$1501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,976 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$146,395
Medicare patients
253
Services billed
1,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter161$147,870
OzempicSemaglutide100$123,539
FarxigaDapagliflozin Propanediol60$59,733
MounjaroTirzepatide36$45,657
EliquisApixaban31$37,175
Tresiba Flextouch U-100Insulin Degludec29$33,595
JanuviaSitagliptin Phosphate38$32,041
XareltoRivaroxaban42$31,322
TrulicityDulaglutide18$26,617
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen674$21,706
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog26$21,057
SuboxoneBuprenorphine Hcl/Naloxone Hcl24$19,512
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$17,023
EntrestoSacubitril/Valsartan12$16,066
Repatha SureclickEvolocumab16$15,014

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$747$147,870161 claims
Novo NordiskOzempic$2,366$123,539100 claims
AstraZenecaFarxiga, Breztri Aerosphere$842$76,75587 claims
Lilly USA, LLCMounjaro, Trulicity$852$72,27354 claims
PfizerEliquis$771$37,17531 claims
Johnson & JohnsonXarelto$506$31,32242 claims
Indivior Inc.Suboxone$18$19,51224 claims
NovartisEntresto$20$16,06612 claims
AbbVieLinzess$764$13,97027 claims
Astellas Pharma US IncMyrbetriq$369$10,35512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Battle Creek

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →